Close Menu

Luminex has recently announced two more moves into the diagnostic field with its xMAP technology. Last week, the company struck a licensing deal with Celera Diagnostics, and the week before it announced plans for spinning out its Rules-Based Medicine (RBM) diagnostics project into a company of the same name that would become a partner for Luminex.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Centers for Disease Control and Prevention has identified a small group of breakthrough COVID-19 cases, the Wall Street Journal reports.

The New York Times reports that the US Department of Defense is to use genetic genealogy approaches to identify the remains of unknown soldiers.

Vox and Nature discuss the importance of preparing for the next pandemic.

In Nature this week: comparison of five circulating tumor DNA assays, resequencing analysis of lettuce gives insight into its domestication, and more.

May
05
Sponsored by
Illumina

Adverse drug reactions (ADRs) are responsible for around 5 percent of hospital admissions and occur in 6 percent to 15 percent of hospital stays.